Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

BACKGROUND: The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patients were eligible to take part in the accompanying health...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Blagden, Sarah P, Cook, Adrian D, Poole, Christopher, Howells, Lesley, McNeish, Ian A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, James, Elizabeth C, White, Ian R, Perren, Timothy, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Kaplan, Richard, Ledermann, Jonathan A, Clamp, Andrew R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lancet Pub. Group 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327508/
https://ncbi.nlm.nih.gov/pubmed/32615110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30218-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller